Coronavirus News Roundup September 19 September 25
For some SARS-CoV-2 vaccine makers, a vaccine “could meet the companies’ benchmarks for success if it lowered the risk of mild COVID-19, but was never shown to reduce moderate or severe” COVID-19, nor the risk of hospitalization, intensive care admission or death, according to an essay published 9/22/20 in The New York Times. This statement pertains to vaccines being developed by Moderna, by Pfizer, and by AstraZeneca, the essay states. The benchmarks should be higher, the authors contend....